Equity Research Analysts at Liberum Capital Didn’t Change their “Buy” rating for BM European Value Retail (LON:BME). The PT is GBX 475.00; Bellicum Pharmaceuticals, Inc. (BLCM) Had 10 Bullish Analysts

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Logo

They currently have a GBX 475.00 target price per share on BM European Value Retail (LON:BME). Liberum Capital’s target would suggest a potential upside of 18.51% from the company’s last stock price. This was disclosed to clients in a research report on Tuesday, 24 April.

Among 11 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Bellicum Pharmaceuticals Inc had 23 analyst reports since July 24, 2015 according to SRatingsIntel. Zacks downgraded Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) on Monday, September 21 to “Sell” rating. The stock has “Buy” rating by Citigroup on Friday, July 24. Cantor Fitzgerald initiated the stock with “Buy” rating in Wednesday, November 2 report. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, June 23. Guggenheim upgraded the stock to “Buy” rating in Friday, September 11 report. The firm has “Buy” rating given on Monday, June 12 by Jefferies. Raymond James initiated Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) on Thursday, December 1 with “Outperform” rating. SunTrust initiated the stock with “Buy” rating in Friday, June 3 report. The company was downgraded on Wednesday, January 31 by Wells Fargo. Wells Fargo upgraded the shares of BLCM in report on Thursday, April 12 to “Outperform” rating. See Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) latest ratings:

11/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0000 Maintain
12/04/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Outperform Upgrade
16/02/2018 Broker: Citigroup Rating: Buy New Target: $27.0
31/01/2018 Broker: SunTrust Rating: Buy New Target: $18.0
31/01/2018 Broker: Wells Fargo Rating: Hold New Target: $6.0 Downgrade

Investors sentiment decreased to 1.1 in 2017 Q4. Its down 0.53, from 1.63 in 2017Q3. It fall, as 2 investors sold B&M European Value Retail S.A. shares while 8 reduced holdings. 4 funds opened positions while 7 raised stakes. 1.20 million shares or 0.74% less from 1.21 million shares in 2017Q3 were reported. First Allied Advisory Ser holds 0.05% or 33,503 shares in its portfolio. Ameriprise Financial has 0% invested in B&M European Value Retail S.A. (LON:BME) for 16,045 shares. Atlantic Tru Gru Ltd Limited Liability Company holds 0% of its portfolio in B&M European Value Retail S.A. (LON:BME) for 100 shares. 52,034 were reported by Invesco Limited. Wells Fargo Com Mn has invested 0% in B&M European Value Retail S.A. (LON:BME). Reilly Fincl Ltd Limited Liability Company reported 710 shares stake. Bb&T Secs Lc owns 11,848 shares. Advisory Net Ltd Liability reported 0% stake. 136,373 are held by Morgan Stanley. 1St Source State Bank invested 0.02% of its portfolio in B&M European Value Retail S.A. (LON:BME). Cetera Advisor Ltd Company holds 13,527 shares or 0.02% of its portfolio. The Wisconsin-based Northwestern Mutual Wealth has invested 0% in B&M European Value Retail S.A. (LON:BME). Fincl Bank Of America De holds 0% or 747,721 shares. Citigroup holds 0% of its portfolio in B&M European Value Retail S.A. (LON:BME) for 386 shares. Stratos Wealth Ptnrs has invested 0% in B&M European Value Retail S.A. (LON:BME).

B&M European Value Retail S.A. operates as a general merchandise value retailer in the United Kingdom and Germany. The company has market cap of 4.01 billion GBP. The Company’s stores offer products in various categories, such as home furnishings and adornments, electricals, toys, clothing and footwear products, household goods, toiletries, foods, confectioneries, soft drinks, alcohol, Halloween and Christmas goods, giftware, stationery and crafts, pet care products, DIY and decorating products, and travel accessories, as well as gardening, outdoor, and leisure products. It has a 26.2 P/E ratio. The firm operates approximately 537 stores under the B&M brand in the United Kingdom; and 75 stores under the Jawoll brand in Germany.

Among 18 analysts covering BM European Value Retail (LON:BME), 14 have Buy rating, 2 Sell and 2 Hold. Therefore 78% are positive. BM European Value Retail has GBX 500 highest and GBX 190 lowest target. GBX 398.88’s average target is -0.48% below currents GBX 400.8 stock price. BM European Value Retail had 191 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 7 by Citigroup. The firm earned “Sell” rating on Tuesday, November 15 by Haitong Securities. The stock has “Buy” rating by Citigroup on Friday, September 4. On Wednesday, July 19 the stock rating was maintained by HSBC with “Buy”. The stock has “Buy” rating by Citigroup on Thursday, January 5. On Wednesday, November 15 the stock rating was maintained by JP Morgan with “Neutral”. The stock of B&M European Value Retail S.A. (LON:BME) has “Buy” rating given on Thursday, January 5 by Canaccord Genuity. Peel Hunt maintained the stock with “Buy” rating in Friday, April 15 report. HSBC maintained B&M European Value Retail S.A. (LON:BME) rating on Thursday, January 5. HSBC has “Buy” rating and GBX 350 target. The stock has “Buy” rating by Deutsche Bank on Monday, April 11.

The stock increased 0.93% or GBX 3.7 during the last trading session, reaching GBX 400.8. About 443,354 shares traded. B&M European Value Retail S.A. (LON:BME) has 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company has market cap of $307.96 million. The Company’s clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. It currently has negative earnings. The companyÂ’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.

The stock decreased 4.26% or $0.32 during the last trading session, reaching $7.2. About 1.11M shares traded. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has declined 43.51% since April 24, 2017 and is downtrending. It has underperformed by 55.06% the S&P500.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Ratings Chart